BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease - Wikidata - awgldk - TriplyDB

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease

http://www.wikidata.org/entity/Q33976971

about

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Enzyme-Free Detection of Mutations in Cancer DNA Using Synthetic Oligonucleotide Probes and Fluorescence Microscopy Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials.Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?T Oligo-Primed Polymerase Chain Reaction (TOP-PCR): A Robust Method for the Amplification of Minute DNA Fragments in Body Fluids.Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Cell-free DNA as a novel marker in cancer therapy.The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.The potential use of urine cell free DNA as a marker for cancer.Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study.Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease.BRAF mutation as a novel driver of eosinophilic cystitis.Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.Assessment of BRAF(V600E) mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction.Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.Urine test for EGFR analysis in patients with non-small cell lung cancer.CNS Erdheim-Chester Disease: A Challenge to Diagnose.Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis.The cancer bloodhounds.

P2860

Q27853371-8C1E6083-EA82-4192-9E9F-39F8DAF15BAF Q35757099-8B464FB6-9C09-4C2F-A94C-4CDAB59ECE9F Q36288987-1DBF94E5-4FCB-4DC4-BEE5-6DB202B9CA2A Q36962764-98F95BE5-CDE8-454A-876D-D331CF66279B Q37160293-035CA88A-ED14-4230-B610-253EB09F9C88 Q37242412-17C8FC48-1CF4-404D-AA76-0D0CA6322CF4 Q37588990-4978B34D-12A0-4005-BE81-B1C711C14FD4 Q37709156-88A649A7-9DF1-4153-ADEC-94FB34F99E29 Q38376337-E8019DE0-E4C0-4B7E-9108-F1E3C949FBE5 Q38547170-13B07ECC-61C9-46E4-9E79-DF9BE18BAC25 Q38620826-8A0A2007-55C5-45C7-8846-49ABBC17857E Q38994581-226166EF-A409-433F-B724-119FF81FF541 Q39163320-66EE2EFE-F4CE-47DE-94C2-BFBF87928585 Q39397373-5E1F7F64-3A58-46D3-84C1-AF0D23932698 Q40084437-8F637F9C-28D4-4543-AF6C-47CAE31EB04A Q40229747-180DAB83-8E7B-44F1-B2A0-34D837F8D412 Q40464058-3F0A17D8-9801-4A95-BB6E-72F6F0F7436B Q40486824-5D31E810-2D43-4DFE-9EDD-09CA2693D1BF Q46633214-13C9489D-D7BF-465E-A3E8-139148BD6C66 Q47564108-32E18A91-F7BA-494C-BE30-4A4E11FF16A2 Q47592137-5312E8D2-6B66-477B-B99C-60AAE08A8DDC Q49568680-A56E512A-3DE0-4B9A-8475-2FB6C59D2657 Q52642826-7897CFDF-715C-4E53-AEF0-CF2D230CC944 Q54459424-92B4CF4F-801C-4EBC-A143-C15F13F1547F

P2860

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease

http://www.wikidata.org/entity/Q33976971

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

BRAF V600E mutations in urine ...... s with Erdheim-Chester disease

@ast

BRAF V600E mutations in urine ...... s with Erdheim-Chester disease

@en

type

label

BRAF V600E mutations in urine ...... s with Erdheim-Chester disease

@ast

BRAF V600E mutations in urine ...... s with Erdheim-Chester disease

@en

prefLabel

BRAF V600E mutations in urine ...... s with Erdheim-Chester disease

@ast

BRAF V600E mutations in urine ...... s with Erdheim-Chester disease

@en

P1433

Q33976971-70F10B89-5309-434F-AA21-F5B81D97865B

P1476

Q33976971-84853ABF-9F58-499A-AA40-DCA3572D541B

P2093

Q33976971-01F25811-EC9F-45F0-888A-812C85111E86

Q33976971-0A202518-1128-4A55-89D1-DBAB58D72275

Q33976971-160E9620-1FD0-443D-A4DA-68F9F4CAA704

Q33976971-52616D0F-0594-4148-BF10-C7842AF81E7A

Q33976971-72A0D35B-F9EB-4518-BA47-64FC5B21E8AA

Q33976971-77CF8A64-D624-48BB-A7DA-FB2465042A6D

Q33976971-AE402192-7A82-43CE-8D9F-DD7DCCE08617

Q33976971-C220454A-D53C-4063-A542-A03D7DBA63EC

Q33976971-C6EF1A28-6F7B-4EF3-B723-DA5D99137726

Q33976971-FD99F475-282C-4E8C-AC27-1BA24888182D

P2860

Q33976971-065E3426-0ED4-485A-98C6-CA77D3543F10

Q33976971-08980C22-B262-4A69-8759-F15B21F6A801

Q33976971-137B7F60-9D57-48F5-B238-E636BCCA21F1

Q33976971-147E629E-FB4B-48BB-90B3-CFA09FA4E99F

Q33976971-19E62459-F90E-4BB0-BE16-4F2A3E04F609

Q33976971-20ABCEF2-B7FC-4767-AB4D-A96C15A8E285

Q33976971-2A9D9431-DBE4-4869-B3AB-A3CB0BD88AF8

Q33976971-4F16F78F-10B6-47F6-8A62-C5C40C93F347

Q33976971-A06AC507-7A50-4E63-A289-4637167ECC37

Q33976971-A4EA4A9E-159F-4000-93F9-012A41B5C1B4

P304

Q33976971-35353D8F-DCB6-4DA3-B7DA-B52279FBB1A2

P31

Q33976971-BB34DE0E-BAFB-4DF9-97F9-93F43FBF05B4

P356

Q33976971-E85F6EDD-A152-41EA-814B-606BB6666686

P407

Q33976971-58DC2F1A-DAF2-44F0-870C-F3F6A7156433

P433

Q33976971-31071F05-044A-478E-926A-53F4826BD650

P478

Q33976971-F0110E94-AB1F-4459-9962-22C92D5ADE63

P50

Q33976971-1EFB8692-D04F-4A4F-B663-71D9C73B74B2

Q33976971-8CFD6EF8-2451-460B-A8D7-75B5C13E792A

Q33976971-8F7DA2F3-BBCE-4587-9311-EB09820185C7

P577

Q33976971-F401380F-45B5-422B-AB60-824F50ECF314

P5875

Q33976971-7C1CC175-EAB2-4B18-915A-5BE3E49649F1

P698

Q33976971-BFC6C91A-2996-4F3F-B6A1-55E0C15916D3

P932

Q33976971-86CFA3B0-B815-46A5-8864-03984360957E

P356

ONCOTARGET.1964

P1433

P1476

BRAF V600E mutations in urine ...... s with Erdheim-Chester disease

@en

P2093

Cecile Rose T Vibat

http://www.w3.org/2001/XMLSchema#string

Goran Cabrilo

http://www.w3.org/2001/XMLSchema#string

Jason C Poole

http://www.w3.org/2001/XMLSchema#string

Karena Kosco

http://www.w3.org/2001/XMLSchema#string

Latifa Hassaine

http://www.w3.org/2001/XMLSchema#string

Lorieta Leppin

http://www.w3.org/2001/XMLSchema#string

Mark G Erlander

http://www.w3.org/2001/XMLSchema#string

Patrick P Lin

http://www.w3.org/2001/XMLSchema#string

Vanda M Stepanek

http://www.w3.org/2001/XMLSchema#string

Veronica R Holley

http://www.w3.org/2001/XMLSchema#string

P2860

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

Circulating mutant DNA to assess tumor dynamics

Response of histiocytoses to imatinib mesylate: fire to ashes

CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Analysis of circulating tumor DNA to monitor metastatic breast cancer

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

P304

3607-3610

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1964

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Funda Meric-Bernstam

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263741528

http://www.w3.org/2001/XMLSchema#string

P698

25003820

http://www.w3.org/2001/XMLSchema#string

P932

4116506

http://www.w3.org/2001/XMLSchema#string